Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan.
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.
J Diabetes Investig. 2020 Nov;11(6):1422-1425. doi: 10.1111/jdi.13302. Epub 2020 Jun 24.
Molecular mechanism underlying glucagon-like peptide-1 exertion of cardioprotective effects in glucagon-like peptide-1 receptor-dependent and -independent manners. Glucagon-like peptide-1 (28-36a) enters coronary artery endothelial cells through macropinocytosis and binds to mitochondrial trifunctional protein-α, shifting substrate utilization to increase adenosine triphosphate production and modulating a adenosine triphosphate-sensor soluble adenylyl cyclase, thereby producing cyclic adenosine monophosphate and activating protein kinase A to exert cytoprotection from oxidative injury.
胰高血糖素样肽-1 发挥其心脏保护作用的分子机制：依赖于胰高血糖素样肽-1 受体和不依赖于胰高血糖素样肽-1 受体的方式。胰高血糖素样肽-1（28-36a）通过巨胞饮作用进入冠状动脉内皮细胞，并与线粒体三功能蛋白-α结合，改变底物利用以增加三磷酸腺苷的产生，并调节三磷酸腺苷传感器可溶性腺苷酸环化酶，从而产生环磷酸腺苷并激活蛋白激酶 A，发挥抗氧化损伤的细胞保护作用。
